Holen Sie sich die Stockscreener-App
46.39
3.07%
-1.47
Vorhandelsmarkt:
45.89
-0.50
-1.08%
Schlusskurs vom Vortag:
$47.86
Offen:
$47.96
24-Stunden-Volumen:
1.11M
Relative Volume:
0.96
Marktkapitalisierung:
$3.68B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-7.8098
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-2.85%
1M Leistung:
-7.59%
6M Leistung:
+2.91%
1J Leistung:
+40.45%
1-Tages-Spanne:
$45.91
$48.23
1-Wochen-Bereich:
$45.91
$49.45
52-Wochen-Spanne:
$29.02
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
46.39 | 3.78B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
What analysts say about PTC Therapeutics Inc. stockPhenomenal wealth increase - jammulinksnews.com
Is PTC Therapeutics Inc. a good long term investmentExceptional market positioning - jammulinksnews.com
Cwm LLC Buys 14,139 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results - Kilgore News Herald
What drives PTC Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Pega to Announce Financial Results for the Second Quarter of 2025 and Host Conference Call and Webcast - Yahoo.co
Pierre Gravier Sells 2,516 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Edgestream Partners L.P. Makes New $418,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
William Blair Predicts Weaker Earnings for PTC Therapeutics - MarketBeat
PTC Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
William Blair Forecasts Lower Earnings for PTC Therapeutics - MarketBeat
What makes PTC Therapeutics Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru
PTC Therapeutics Advances PKU Treatment with Sepiapterin Study - TipRanks
PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors - TipRanks
Brokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $65.00 - MarketBeat
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance - GlobeNewswire Inc.
PTC Therapeutics stock gets Buy rating from UBS ahead of FDA decision - Investing.com Canada
Allspring Global Investments Holdings LLC Acquires Shares of 10,287 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Banque Pictet & Cie SA Acquires New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
PTC Therapeutics: Regulatory Catalysts and Financial Fortitude Position the Company for a Breakout Year - AInvest
Cantor Fitzgerald Has Negative View of PTCT FY2026 Earnings - MarketBeat
PTCT FY2025 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation - Seeking Alpha
PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - inkl
EC approves PTC Thera’s Sephience for PKU - The Pharma Letter
Germany will be first launch for PTC's phenylketonuria drug - pharmaphorum
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - PR Newswire
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches - Yahoo Finance
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Company Announcement - Financial Times
10 Biotech Stocks Screaming a Buy - Insider Monkey
PTC Therapeutics (PTCT): Truist Securities Initiates Coverage with 'Buy' Rating | PTCT Stock News - GuruFocus
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - MarketScreener
Truist Financial Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Gains Buy Rating with Promising Drug Pipeline | PTCT Stock News - GuruFocus
When the Price of (PTCT) Talks, People Listen - news.stocktradersdaily.com
GAMMA Investing LLC Increases Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):